Key Insights

Highlights

Treatment Research

3 treatments under study, led by Tislelizumab Combined With Lenvatinib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07480382Not ApplicableNot Yet RecruitingPrimary

Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC

Showing all 1 trials

Research Network

Common Treatments

  • Tislelizumab Combined With Lenvatinib1
  • Liver Venous Deprivation Lvd1
  • Conventional Transarterial Chemoembolizationctace1

Active Sponsors

  • Hong Wu1

Top Investigators

Activity Timeline